Recurrent Clostridium Difficile Infection Clinical Trial
Official title:
Dietary Optimization of Microbiome Recovery Following Fecal Microbiota Transplantation
NCT number | NCT05826418 |
Other study ID # | rCDI |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2023 |
Est. completion date | August 1, 2025 |
Recurrent Clostridioides difficle infection (rCDI) is a very significant problem in its own right and current fecal microbiota transplant (FMT) -based therapeutics will benefit from their optimization for this indication. It is likely that appropriate nutritional support coupled with microbiota-based drugs will yield superior clinical outcomes. However, both diet and gut microbiome are very complex. This project, which is based on a wealth of FMT experience, both clinical and investigational, over the past decade along with the novel techniques developed to identify dietary patterns and food groups that explain the most variation in gut microbiome, offers an ideal platform for performing systematic research in nutritional support that promotes gut microbiota health. The purpose is to Generate preliminary data with regards to tolerability of the Microbiota enhancing and nourishing diet (MEND) and its effects on the fecal microbiota in rCDI patients following FMT with the goal of developing larger clinical trials aimed to optimize post-FMT dietary management.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | August 1, 2025 |
Est. primary completion date | August 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Informed consent - Clinical plans to undergo FMT therapy for treatment of rCDI (= 2 CDI recurrences following the initial episode within 1 year without contraindications to the treatment) - Ability to comply with study requirements - Age at least 18 years old Exclusion Criteria: - Underlying IBD - History of stomach surgery or bowel resection - Anticipated antibiotic exposure during the study period - Advanced liver disease - Ongoing alcohol or drug abuse - Pregnancy - Any reason felt by the investigator to complicate the feasibility of participation |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Participant acceptance of the diet | Diet acceptability questionnaire: Includes 7 questions each with minimum and maximum values (1 and 7) and higher scores mean better outcomes. | 4 weeks | |
Primary | Participant compliance with study procedures | 24-hr dietary recalls will be used to assure adherence with the study diet | intervention to 4 weeks | |
Secondary | Bacterial diversity | Shannon diversity index | 1 week | |
Secondary | Bacterial diversity | Shannon diversity index | 4 weeks | |
Secondary | Bacterial diversity | Shannon diversity index | 3 months | |
Secondary | Similarity to donor bacterial composition | Using SourceTracker: which uses modeling based on 16S rDNA sequencing, is the measurement tool used to assess the measure | 1 week | |
Secondary | Similarity to donor bacterial composition | Using SourceTracker: which uses modeling based on 16S rDNA sequencing, is the measurement tool used to assess the measure | 4 weeks | |
Secondary | Similarity to donor bacterial composition | Using SourceTracker | 3 months | |
Secondary | Bacterial composition | Relative abundance of specific bacteria previously documented to be predictive of successful FMT outcomes with respect to CDI recurrence | 1 week | |
Secondary | Bacterial composition | Relative abundance of specific bacteria previously documented to be predictive of successful FMT outcomes with respect to CDI recurrence | 4 weeks | |
Secondary | Bacterial composition | Relative abundance of specific bacteria previously documented to be predictive of successful FMT outcomes with respect to CDI recurrence | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05201079 -
Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
|
Phase 3 | |
Terminated |
NCT01226992 -
Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04960306 -
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
Completed |
NCT03462459 -
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
|
Phase 2 | |
Recruiting |
NCT06237452 -
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
Completed |
NCT03497806 -
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
|
Phase 2 | |
Suspended |
NCT01202630 -
BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
|
Phase 3 | |
Terminated |
NCT03973697 -
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
|
Phase 2 | |
Completed |
NCT03353506 -
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection
|
Phase 2 | |
Completed |
NCT01925417 -
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
|
Phase 2 | |
Available |
NCT03786900 -
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
|